Houston Methodist to Highlight Leading Otolaryngology Research at COSM 2025

Houston Methodist will showcase its cutting-edge research in otolaryngology at the upcoming Combined Otolaryngology Spring Meetings (COSM).

Faculty and residents from Houston Methodist Hospital will lead five presentations at COSM 2025, which is being held in New Orleans May 14-18. The presentations underscore the hospital's leading role advancing treatments and surgical approaches in otolaryngology-head and neck surgery.

A premier educational and technological forum, COSM gathers top otolaryngology professionals from around the nation to exchange knowledge, innovate patient care and disseminate groundbreaking research.

Houston Methodist's participation in COSM 2025 includes the following presentations:

Risk Factors for Revision Rhinoplasty

May 14, 3:20 p.m. | AFPRS Meeting

Houston Methodist resident Dr. Heli Majeethia's study, supervised by principal investigator Dr. Anthony E. Brissett, explores demographic and psychological factors influencing the likelihood of patients wanting revision rhinoplasty. The results suggest that previous cosmetic surgeries (not multi-procedure cosmetic surgery) and gender (female) significantly predict revision risk. They also suggest mental health conditions do not show an additional risk.

Opioid Prescribing Trends After Sinus Surgery

May 16 | TRIO Meeting

Dr. Heli Majeethia will present research evaluating opioid prescription practices before and after the adoption of the 2021 AAO-HNS guidelines. This extensive study reveals a significant reduction in opioid prescriptions without negative effects on patient pain control or readmission rates post-surgery. Principal investigators include Dr. Omar Ahmed and Dr. Mas Takashima.

Chronic Rhinitis Scientific Session

May 18, 8–9 a.m. | ARS Meeting

Dr. Omar Ahmed will moderate a session highlighting the latest advancements and research in managing chronic rhinitis and spotlighting Houston Methodist's major contributions toward improving clinical practices and patient outcomes.

FESS vs. Biologic Therapy for Chronic Rhinosinusitis with Nasal Polyps: Systematic Review and Meta-Analysis

May 18, 10:16 a.m. | ARS Meeting

This study reviews outcomes comparing Functional Endoscopic Sinus Surgery (FESS) with biologic therapies in patients with chronic rhinosinusitis with nasal polyps. Findings indicate FESS offers superior symptom improvement, though biologic therapy (Dupilumab) yielded better olfactory outcomes. Presented by Dr. Chadi Makary (West Virginia University), with Houston Methodist first authors Dr. Heli Majeethia and Dr. Zain Mehdi, guided by principal investigators Dr. Mas Takashima and Dr. Omar Ahmed.

Weight Loss Improves Chronic Rhinosinusitis Outcomes

May 18, 10:34 a.m. | ARS Meeting

This population-based study demonstrates that sustained weight loss significantly alleviates chronic rhinosinusitis symptoms, reduces antibiotic use and decreases related medical visits. The study, guided by principal investigators Drs. Omar Ahmed and Mas Takashima, will be presented by Houston Methodist resident Dr. Zain Mehdi.